Phase I Clinical Trials

• CT179 · PDF SON-1010 (IL12-F H AB) synergizes with trabectedin in advanced soft-tissue sarcoma Sant Chawla, Victoria Chua, Neal Chawla, Erlinda M. Gordon, John Cini, Richard Kenney
• CT180 · PDF Safety and efficacy of pucotenlimab combined with standard chemotherapy regimens in the preoperative treatment of pediatric patients with intermediate or high-risk rhabdomyosarcoma: A phase I/II study Yi Que, Suying Lu, Feifei Sun, Juan Wang, Junting Huang, Jia Zhu, Yu Zhang, Mengjia Song, Zijun Zhen, Yizhuo Zhang
• CT182 · PDF Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma (mRCC): A randomized phase I trial Regina Barragan Carrillo, Miguel Zugman, Bertrand Routy, Mallia Geiger, Xiaochen Li, Nazli Dizman, Hedyeh Ebrahimi, Salvador Jaime-Casas, Nicholas Salgia, Joann Hsu, Daniela V. Castro, Benjamin D. Mercier, Koral Sha, Sreya Duttagupta, Tanya B. Dorff, Neal S. Chawla, Ruchi Agarawal, Ekta Kapoor, Marcin Kortylewski, Alex Chehrazi-Raffle, Arielle Elkrief, Sumanta K. Pal
• CT183 · PDF Phase Ib clinical evaluation of a novel CD55- and FcRn-bioselected RNA oncolytic virus, IVX037, combined with sintilimab (anti-PD-1) in advanced microsatellite-stable colorectal cancer Jia Liu, Sophia Frentzas, Ganessan Kichenadasse, Timothy Price, Niall Tebbutt, Shehara Mendis, Rafid Al-Asady, Eugene Hsu, Mei Chan, Phillip Tran, Darren Shafren, Oksana Zdanska, Mark Wong
• CT184 · PDF Preliminary results of first-line botensilimab (BOT) and balstilimab (BAL) optimization in microsatellite stable colorectal cancer (MSS CRC) without liver, bone, or brain metastasis (BBOpCo) Nicholas C. Devito, Emily Bolch, Aman Opneja, Hope Uronis, Lisa Vlastelica, Gerard C. Blobe, John W. Hickey, Yuexi Kylee Li, Kevin S. Tanager, Cheryl H. Chang, Jingchen Chai, Kara Bonneau, Niharika B. Mettu, Michael A. Morse, Tucker W. Coston, Shiaowen David Hsu, Carol A. Wiggs, Donna Niedzwiecki, Dana A. Warren, John H. Strickler
• CT185 A phase 1 trial of M3814 (peposertib) in combination with lutetium 177 DOTATATE for metastatic well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Aman Chauhan, Susanne Arnold, Donglin Yan, Rani Jayswal, Vineeth Sukrithan, Daneng Li, Riham Khouli, Heliosa Soares, Jan Beumer, Steven Gore, Lorraine Pelosof, Elise Kohn, William Carson, Anthony Lowell
• CT186 · PDF Pulmonary toxicity associated with increased 6-OH-paclitaxel exposure in pancreatic cancer patients treated with nab-paclitaxel, gemcitabine and cobicistat: Results of the IntenSify trial Nicolas Hohmann, Martin R. Sprick, Marietta Kirchner, Lucian Le Cornet, Azaz Ahmed, Markus Kratzmann, Joge-Jossy Tonison, Jacek Stermann, Amina Cheikh Rouhou, Karen Steindorf, Stefan Delorme, Heinz-Peter Schlemmer, David Czock, Jürgen Burhenne, Jacek Hajda, Jens T. Siveke, Thomas Seufferlein, Albrecht Stenzinger, Guy Ungerechts, Dirk Jäger, Andreas Trumpp, Christoph Springfeld
• CT187 · PDF Immunogenicity of the therapeutic HPV16-specific cancer vaccine abipapogene suvaplasmid (VB10.16) in combination with pembrolizumab given as 1L treatment for HPV16+ PD-L1+ r/m oropharyngeal cancer: Preliminary results from phase 1 of the VB-C-03 trial Caroline Even, Saira Khalique, Marc B. Oliva, Marie Vinches, Marta G. Arnau, Kaja C. G. Berg, Ingvild S. Leikfoss, Aleksandra Urban, Marthe J. Jørgensen, Christian W. Wold, Judith Wong, Miriam Ragle Aure, Lena Finnesand, Roberto Oliveri, Agnete B. Fredriksen, Åse Bratland
• CT188 · PDF Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial Moran Amit, Robert Saddawi-Konefka, Shorook Naara, Fred Netto, Fred Netto, Chen F Fushun, Yen Vu, Sophie Li, Tongxin Xie, Shamima Akhter, Hinduja Sathishkumar, Tieling Zhou, Sreyashi Basu, Luana Sousa, Neal Akhave, Theresa Hofstede, Ann Gillenwater, Ed Diaz, Kirsten Pytynia, Lorena Gomez, Michelle Williams, Andrew Sikora, Jeffrey Myers, Humam Kadara, James Allison, Sharma Padmaneee, Mark Chambers
• CT189 · PDF Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors Rohit Thummalapalli, Ming Lu, Alexander Spira, Amr Mohamed, Rahul Aggarwal, Yu Wang, Namrata Vijayvergia, Jordi Rodon, Andrew Scott Paulson, Pingkuan Zhang, Hui Yang, Yuan Xin, Jingmin Wen, Jie Chen
• CT190 · PDF Brexu-cel + dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia Nikeshan Jeyakumar, Parveen Shiraz, Evan Weber, Alyssa Kanegai, Caroline Wagner, Arvind Ramakrishnan, Bita Sahaf, Matthew Frank, Saurabh Dahiya, Melody Smith, Surbhi Sidana, Crystal Mackall, David Miklos, Lori Muffly
• CT191 · PDF The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of a Phase I study Jan Bewersdorf, Andriy Derkach, Amer Zeidan, Emily Burton, Katherine Kan, Marissa Guiliani, Jeetayu Biswas, Michael Mauro, Brian Chernak, Tamanna Haque, Nikolai Podoltsev, Prithviraj Bose, Omar Abdel-Wahab, Ross Levine, Raajit Rampal
• CT192 · PDF The first report of patients with solid tumors treated with LP-118, a novel Bcl-2/Bcl-xL dual inhibitor Qing Zhou, Xiaorong Dong, Jianya Zhou, Duidui Hong, Yue Shen, Fenlai Tan, Xiang Xiao, Yejiang Lou, Jiemin Xie, Yilong Wu
• CT193 · PDF Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial Pedro Rocha, Manish Patel, Yi-Long Wu, Jun Zhao, Grace Dy, María Eugenia Olmedo García, Qiming Wang, Valentina Gambardella, Oscar Juan-Vidal, Afshin Dowlati, David Vicente Baz, Alexander Spira, Anne C. Chiang, Yingying Du, Martin Gutierrez, Xiaorong Dong, Jie Hu, Mariam Alexander, Haiyong Wang, Wenxiu Yao, Liza Villaruz, Zhen Wang, Pingkuan Zhang, Renke Zhou, Xiao Wang, Luis Paz-Ares
• CT194 · PDF Local administration of tumor infiltrating lymphocytes by hepatic artery infusion in patients with uveal melanoma and liver metastases Axel Nelson, Rebecca Riise, Samuel Alsen, Andrew Wong, Per Carlsson, Sebastian Edman, Jan Holgersson, Roger Olofsson Bagge, Iva Johansson, May Sadik, Lars Edenbrandt, Lisa M. Nilsson, Jonas A. Nilsson, Lars Ny
• CT195 · PDF Fast-manufactured, low IL-2-dependent FAST-TIL for the treatment of advanced melanoma in asian patients: Median 6-month follow-up data from a phase I clinical trial Di Wu, Yuan Fang, Zhen Guo, Jie Liu, Jing Lin, Yaotiao Deng, Shijie Lan, Shuhang Wang, Ganchen Gao, Pengxiang Wang, Xinhua Zhang, Yi Zhao, Yu Chen, Yu Jiang, Ning Li
• CT197 · PDF Phase I study of ERY974 in patients with glypican-3 (GPC-3)-positive advanced solid tumors Haruyasu Murakami, Hidetoshi Hayashi, Kensei Yamagushi, Kei Muro, Taroh Satoh, Tomohiro Nishina, Eisuke Ueda, Chika Ogami, Hitomi Takeshita, Hayato Takahashi, Mikiko Nakamura, Mihiro Toba, Yasutoshi Kuboki
• CT198 · PDF Phase 1 clinical trial of a first-in-class antagomir therapeutic against advanced solid tumors Zdravka Medarova, Siqing Fu, William McKean, Minal Barve, Alex Spira, Daniel Vlock, Lisa Fortin, Susan Duggan
• CT199 · PDF SAR445877: A PD-1-targeted IL-15 mutein selectively activates PD-1+ T cells resulting in therapeutic activity across pre-clinical mouse models and in early human clinical trials Isaraphorn Pratumchai, Marie Bernardo, Julien Tessier, Fatima Menas, Jaroslav Zak, Kristi L. Marquardt, Joon Sang Lee, AHyun Choi, Anthony M. Byers, Mikielia Devonish, Roberto Carrio, Dan Lu, Stella Martomo, Jeegar Patel, Yu-an Zhang, Ingeborg Langohr, Virna Cortez-Retamozo, Dinesh S. Bangari, Angela Hadjipanayis, Xiangming Li, John R. Teijaro, Valeria R. Fantin, Raymond P. Perez, Donald R. Shaffer
• CT200 · PDF Phase I dose-escalation study of ENPP1 inhibitor, vizenpistat, for the treatment of solid tumors Mohan R. Kaadige, Alexis S. Larsen, Trason Thode, Margaux Steinbach, Scott Houston, Srinivas Kasibhatla, Jonathan Northrup, Sunil Sharma

在完整检索应用中浏览本分会场 →